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introduction: Limited evidence exists on effective interventions to improve knowledge 
of preventive medications in patients with chronic diseases, such as stroke. We investi-
gated the effectiveness of a nurse-led intervention, where a component was to improve 
knowledge of prevention medications, in patients with stroke or transient ischemic 
attack (TIA).
Methods: Prospective sub-study of the Shared Team Approach between Nurses and 
Doctors for Improved Risk Factor Management, a randomized controlled trial of risk 
factor management. We recruited patients aged ≥18 years and hospitalized for stroke/
TIA. The intervention comprised an individualized management program, involving 
nurse-led education, and management plan with medical specialist oversight. The 
outcome, participants’ knowledge of secondary prevention medications at 12 months, 
was assessed using questionnaires. A score of ≥5 was considered as good knowledge. 
Effectiveness of the intervention on knowledge of medications was determined using 
logistic regression.
results: Between May 2014 and January 2015, 142 consecutive participants from the 
main trial were included in this sub-study, 64 to usual care and 78 to the interven-
tion (median age 68.9  years, 68% males, and 79% ischemic stroke). In multivariable 
analyses, we found no significant difference between intervention groups in knowledge 
of medications. Factors independently associated with good knowledge (score ≥5) at 
12  months included higher socioeconomic position (OR 4.79, 95% CI 1.76, 13.07), 
greater functional ability (OR 1.69, 95% CI 1.17, 2.45), being married/living with a part-
ner (OR 3.12, 95% CI 1.10, 8.87), and using instructions on pill bottle/package as an 
administration aid (OR 4.82, 95% CI 1.76, 13.22). Being aged ≥65 years was associated 
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with poorer knowledge of medications (OR 0.24, 95% CI 0.08, 0.71), while knowledge 
was worse among those taking three medications (OR 0.15, 95% CI 0.03, 0.66) or ≥4 
medications (OR 0.09, 95% CI 0.02, 0.44), when compared to participants taking fewer 
(≤2) prevention medications.
Conclusion: There was no evidence that the nurse-led intervention was effective for 
improving knowledge of secondary prevention medications in patients with stroke/TIA 
at 12 months. However, older patients and those taking more medications should be 
particularly targeted for more intensive education.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN1268 
8000166370).
Keywords: randomized controlled trial, stroke, nursing intervention, patient medication knowledge, secondary 
prevention
inTrODUCTiOn
Use of evidence-based pharmacological therapies is a recognized 
strategy for controlling vascular risk factors in patients with stroke 
(1–3). In patients with chronic diseases, such as stroke, a major 
factor associated with adherence to medications is adequate 
knowledge regarding the often complex medication regimen (4). 
This includes knowing the name, administration, handling, and 
potential side effects of the medications (5). Moreover, authors 
have reported associations between knowledge of medications 
and control of blood glucose in patients with diabetes (6), con-
trol of blood pressure in those with hypertension (7), and reduc-
tion of adverse outcomes in patients with vascular disease (8). 
However, there is evidence that information needs of patients 
with chronic diseases, regarding their medications, are not being 
met (9).
To empower patients with chronic diseases, it is recommended 
that education and counseling on use of medications is initiated 
during their acute hospital stay (10). This is usually complemented 
by long-term interventions to facilitate effective use of medica-
tions post-discharge (11). Primary care providers, including 
nurses and pharmacists, have important roles in implementing 
these strategies.
Many studies have been conducted to determine the effective-
ness of educational strategies to improve adherence to medications 
in the treatment of chronic diseases (12). However, limited data 
exist on effective interventions to improve knowledge of medica-
tions in this high-risk population. In patients with hypertension, 
there was no evidence that a nursing intervention improved 
knowledge of preventive medications after 12-month follow-up 
(13). The benefit of an intervention to improve knowledge of 
medications in people with stroke has been reported previously 
(14). However, this evidence is limited by a weak methodological 
approach. Clearly, a more robust approach would provide more 
reliable evidence on this topic, this being the rationale for our 
study. We investigated the effectiveness of a nurse-led indi-
vidualized management program for improving knowledge of 
secondary prevention medications in patients with stroke or 
transient ischemic attack (TIA). We hypothesized that survivors 
of stroke or TIA who received our intervention would have better 
knowledge of secondary prevention therapies, when compared to 
those receiving usual care.
MaTErialS anD METHODS
Trial Design and Participants
This was a prospective sub-study of the Shared Team Approach 
between Nurses and Doctors for Improved Risk Factor 
Management (STAND FIRM), a multicenter cluster-randomized 
controlled trial, in patients with stroke/TIA. A detailed descrip-
tion of the design for the STAND FIRM trial has been published 
elsewhere (15). Briefly, participants were recruited from four 
teaching hospitals in Melbourne, Australia: Monash Medical 
Center, Alfred Hospital, Box Hill Hospital, and Dandenong 
Hospital, between January 2010 and November 2013. Eligible 
patients were adults (aged ≥18  years) hospitalized for stroke/
TIA, and living within 50 km of the closest recruitment hospital 
(Figures 1 and 2). We excluded patients recruited to another trial, 
admitted from or discharged to a nursing home, or presenting 
with worsening health condition.
Patients who met the eligibility criteria were randomized to 
either receive usual care or an individualized management pro-
gram in addition to usual care. A computer-generated, blocked 
randomization procedure was undertaken to ensure that each 
recruitment hospital had a balance of patients in each group. This 
was to remove any potential treatment bias as post-acute treat-
ment may vary somewhat at each recruitment hospital. Further, 
as general practitioners (GPs) play a significant role in delivering 
the intervention, randomization was clustered by general practice 
to minimize contamination between the intervention and usual 
care groups. As a result, GPs nominated by the participants, and 
the practice in which they belonged, were randomly allocated to 
either provide usual care only, or the intervention in addition to 
usual care. This meant that a GP participating in the trial, or the 
practice to which the GP belonged, could only treat patients in 
one of the two treatment groups. As a result, GPs and practices 
nominated by newly recruited patients were checked against a list 
of all GPs and practices already participating in the study. If a GP 
or practice nominated by a newly recruited participant already 
had a patient in the study, then the participant was allocated 
FiGUrE 1 | Trial design.
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to the treatment group in which the GP or practice belonged. 
However, if such GP or practice did not already have a patient in 
the study, then the GP or practice was randomly allocated to the 
next random allocation within the block.
In May 2014, a sub-study was initiated to objectively evalu-
ate the effectiveness of the nurse education component of the 
intervention. This initiative was borne out of lack of robust or 
reliable evidence on effective interventions to improve knowledge 
of medications in people with chronic diseases. In the present 
sub-study, we enrolled consecutive participants who were yet 
to undertake 12-month assessments in the STAND FIRM trial. 
Participants were enrolled from both study arms and all four 
recruitment hospitals, and no new selection criteria were used. 
Ethics approval was obtained from all participating hospitals and 
Monash University (HREC number 2011000331), and written 
informed consent was obtained from all participants. STAND 
FIRM trial is registered with the Australian New Zealand Clinical 
Trials Registry (ACTRN12680000166370).
Usual Care
Participants randomized to usual care received standard care 
available in the stroke prevention clinic of the participating 
hospitals and in general practice. Standard care may have involved 
provision of education and advice on secondary prevention by 
care providers, including community-based pharmacists.
intervention
The intervention group received an individualized management 
program, comprising a chronic disease management (CDM) plan 
and two home visits by nurses to provide tailored education for 
secondary prevention, in addition to usual care (Figure 1). An 
unblinded nurse, in consultation with a stroke specialist, spe-
cifically tailored the CDM plan to each participant using health 
information obtained by a blinded assessor at baseline assess-
ment. The CDM plan comprised clear health goals for secondary 
prevention, including adherence to recommended therapies. This 
plan was then provided to the GP to facilitate the care of their 
patients.
Prior to involving GPs in the intervention, an unblinded nurse 
conducted an in-home visit with participants to discuss their 
health goals, provide tailored education, and discuss strategies to 
overcome barriers. Specifically, the nurse reviewed medications 
prescribed for secondary prevention and provided formal educa-
tion or counseling on the use of these medications. Information 
FiGUrE 2 | Flow chart of participants through the study. IMP, individualized management program; *Participants may have more than one reason for 
exclusion; †Severe or deteriorating condition includes concurrent illness, dementia, palliated, or deceased.
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provided on medications included dosage and time of adminis-
tration, benefits of adherence, and self-management skills, such 
as identifying and managing potential side effects. Nurse educa-
tion was facilitated by the use of brochures provided by Australia’s 
Stroke Foundation (16), and standard syllabus for education on 
secondary prevention of stroke (Data Sheet S1 in Supplementary 
Material). The syllabus comprised a component on prevention 
medications (Page 6; Data Sheet S1 in Supplementary Material). 
Participants were also invited to ask questions about their medi-
cations or general recovery. Finally, the nurse organized appoint-
ments for participants to discuss their CDM plan with their GP. 
At 3 months after baseline, the CDM plan was reviewed and the 
education visit was repeated, taking into account any changes in 
medication regimen.
Baseline and Follow-up assessments
Baseline data on details of the stroke were obtained from the hos-
pital records of the patients, while demographic data, details of 
prescribed medications, and standardized assessment of mental 
and functional status were obtained by a blinded assessor during 
an in-home patient visit (median 10 weeks post-discharge). The 
London Handicap Scale (LHS) was used to measure functional 
disability, and the Hospital Anxiety and Depression Scale (HADS) 
for mood disorders, at baseline, 3, and 12 months.
Outcome assessment
The study outcome comprised participants’ knowledge of their 
medications for secondary prevention at 12  months, ascer-
tained by blinded assessors. Recommended therapies assessed 
included three categories: antihypertensive, antithrombotic, 
and cholesterol-lowering medications. Knowledge was assessed 
using a modified version of the McPherson index (6, 17, 18). The 
items comprised name of the medication, purpose, mechanism 
of action, time of administration, knowledge of side effects, and 
what to do when side effects occurred or doses were missed. 
Participants were assessed on only the categories of medications 
they were taking at 12 months; in those taking more than one 
type of medication in each category, one was randomly selected 
for assessment.
For each of the seven items assessed, a correct answer was 
scored 1, and an incorrect answer 0 (Table 1). The overall score 
for each item was the sum of scores for an item divided by the 
number of categories of medications used, giving a maximum 
score of 1 for each item. A similar approach was used for overall 
TaBlE 1 | Scoring algorithm for knowledge of medications.
Knowledge category Medication categorya
antihypertensive antithrombotic Cholesterol lowering Score
Name 1 1 – 2/2 = 1
Purpose 1 0 – 1/2 = 0.5
Mechanism of action 1 1 – 2/2 = 1
Time of Administration 1 0 – 1/2 = 0.5
Knowledge of side effects 1 1 – 2/2 = 1
What to do when there are side effects 1 0 – 1/2 = 0.5
What to do when doses are missed 1 1 – 2/2 = 1
Total score 7 4 – 11/2 = 5.5
aPossible score for each item is 0 for no knowledge and 1 for knowledge.
The above example is for a person who takes an antihypertensive and an antithrombotic agent, but does not take a cholesterol-lowering medication.
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knowledge of medications, but used all items and all categories 
(possible range 0–7). Based on data from previous studies 
(6,  17), and median knowledge score in our study population, 
an individual item score of 1 and a composite score of ≥5 were 
considered as good knowledge.
Statistical analysis
Because of limited data on knowledge of medications both in 
survivors of stroke and the general population, a reliable estimate 
of sample size was not possible. However, in this study, outcome 
data were obtained from as many participants as possible in the 
STAND FIRM cohort.
Continuous variables were summarized as medians and 
quartiles (Q1, Q3), while categorical variables were summarized 
as frequency counts and percentages. In order to assess balance 
between the intervention and control groups at baseline, par-
ticipant characteristics were compared using Wilcoxon rank sum 
test for continuous variables, and χ2 test for categorical variables. 
In cases where cell frequencies were <5, Fisher’s exact test was 
used to compare categorical variables.
All outcome analyses were performed based on intention-
to-treat. Regression analyses were used to determine the effect 
of the intervention on knowledge of medications. A univari-
able logistic regression model was used when knowledge was 
defined as a categorical variable, i.e., a composite score of ≥5 
for good knowledge and <5 for poor knowledge. A univariable 
linear regression model was used when knowledge was defined 
as a continuous variable. In the adjusted analyses, multivariable 
regression models were conducted using stepwise selection 
procedure. The full multivariable models included baseline 
variables such as age, sex, marital status, socioeconomic posi-
tion, educational attainment, type of stroke, and medical his-
tory. The models also included variables obtained at 12 months, 
such as mental and functional status, number of prescribed 
secondary prevention medications, length of use of preven-
tion medications, method by which medications are packaged 
or provided by pharmacist, and method of keeping track of 
medications. Apart from age and sex, that were fixed, only 
variables with a P-value of <0.05 were retained in the final 
model. Similar procedures were used to determine the effect of 
the intervention on the six measured attributes of knowledge 
of medications.
To identify patient factors independently associated with 
knowledge of medications, a stepwise logistic regression model 
was constructed using methods similar to those stated above. To 
further explain the results of the outcome analyses, a sensitivity 
analysis was conducted using a per-protocol dataset. The per-
protocol dataset comprised data from only participants with no 
deviation from the protocol, i.e., participants who received nurse 
home education visits both at baseline and 3 months. Analyses 
were not adjusted for any effect of clustering by general practice 
given the few number of participants in each cluster (average two 
participants per general practice). All analyses were conducted 
using STATA IC (12.0). A two-sided P-value of <0.05 was con-
sidered statistically significant.
rESUlTS
Participant Flow and Baseline 
Characteristics
A total of 563 participants were recruited into the STAND 
FIRM trial, of whom 142 (25%) consecutive participants were 
eligible (i.e., alive and had not undertaken 12-month assessment 
at the time of commencement of the present sub-study), and 
were subsequently enrolled. These comprised 78 participants 
in the intervention group and 64 in the control group, median 
age 68.9 years, 68% male, and 79% ischemic stroke (Figure 2). 
Participants who were not enrolled were more often depressed 
than those who were enrolled (15 vs. 9%, P = 0.044; Table 2). No 
other difference in baseline characteristics was detected between 
participants who were enrolled and those not enrolled in this 
sub-study. The intervention group had greater socioeconomic 
position than the control group (58 vs. 39%, P = 0.007). There 
was no other difference in baseline characteristics between study 
groups.
After the commencement of the present sub-study, there were 
no losses to follow-up. However, 6 (4%) of the 142 consecutive 
participants enrolled to this sub-study were not assessed for 
outcome measures as a result of logistical issues, while another 
3 (2%) were not taking prevention medications at the 12-month 
follow-up. These participants were excluded from outcome 
analyses as there were no data on knowledge of medications. 
Therefore, 133 (94%) participants were assessed at 12  months, 
TaBlE 2 | Baseline characteristics.
Characteristics STanD FirM cohort (n = 533)
not enrolled in sub-study (n = 391) Enrolled in sub-study (n = 142)
Total intervention (n = 78) Control (n = 64)
Aged ≥65 years 246 (62.9) 88 (62.0) 47 (60.3) 41 (64.1)
Female 139 (35.6) 45 (31.7) 20 (25.6) 25 (39.1)
Vocational or higher education 195 (49.9) 84 (59.2) 48 (61.5) 36 (56.3)
High socioeconomic positiona 204 (52.2) 64 (45.1) 45 (57.7) 25 (39.1)
Married or living with partner 256 (65.5) 100 (70.4) 52 (66.7) 48 (75.0)
Type of stroke
Ischemic stroke 303 (77.5) 112 (78.9) 60 (76.9) 52 (81.3)
Intracerebral hemorrhage 31 (7.9) 11 (7.8) 7 (9.0) 4 (6.3)
Transient ischemic attack 57 (14.9) 19 (13.4) 11 (14.1) 8 (12.5)
Recurrent stroke 59 (15.1) 18 (12.7) 9 (11.5) 9 (14.1)
≥2 comorbidities 214 (54.7) 71 (50.0) 34 (43.6) 37 (57.8)
Prescribed secondary prevention medications
Total [median (Q1, Q3)] 2 (2, 3) 2 (2, 3) 3 (3, 4) 3 (3, 4)
≤2 86 (22.0) 35 (24.7) 19 (24.4) 16 (25.0)
3 128 (32.7) 55 (38.7) 33 (42.3) 22 (34.4)
≥4 177 (45.3) 52 (36.6) 26 (33.3) 26 (40.6)
Antihypertensive 330 (84.4) 115 (81.0) 64 (82.1) 51 (79.7)
Cholesterol-lowering 338 (86.5) 124 (87.3) 69 (88.5) 55 (85.9)
Antithrombotic 355 (90.8) 130 (91.6) 70 (89.7) 60 (93.8)
Disability [median LHS score (Q1, Q3)] 0.85 (0.73, 0.93) 0.86 (0.80, 0.97) 0.86 (0.80, 0.97) 0.86 (0.75, 0.97)
Depressed (HADS >7)b 58 (14.9) 12 (8.5) 6 (7.7) 6 (9.4)
Anxious (HADS >7) 77 (19.8) 25 (17.6) 14 (18.0) 11 (17.2)
aStatistical difference in socioeconomic position between intervention and control groups (P = 0.007).
bStatistical difference in proportion of participants with depression between participants enrolled and not enrolled (P = 0.044).
Data are expressed as frequency and proportion unless otherwise stated.
LHS, London Handicap Scale; HADS, Hospital Anxiety and Depression Scale.
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and were included in the outcome analyses. A relative provided 
information for one participant, but in all other instances, the 
information was obtained directly from participants.
Outcome analyses
Overall, at 12 months, the median (Q1, Q3) score for knowledge 
of medications was 5.3 (3.7, 6.7), and 54% of participants had 
good knowledge (score ≥5). In multivariable logistic regression 
(knowledge treated as categorical variable) and linear regression 
(knowledge treated as continuous variable) analyses, there was 
no detectable difference in knowledge of medications for sec-
ondary prevention between intervention and control groups at 
12 months (Table 3). Similar results were obtained for each of the 
seven items that comprised the composite score for medication 
knowledge (Table 3). In the per-protocol analyses, comprising 67 
participants in the intervention group and 61 participants in the 
control group, there was no detectable difference between treat-
ment groups in both the overall knowledge of medications, and 
the measured attributes of knowledge of medications (Table 4).
Factors independently associated with good knowledge of 
medications (score ≥5) at 12  months (Table  5) were having a 
higher socioeconomic position (OR 4.79, 95% CI 1.76, 13.07), 
greater functional ability (OR 1.69, 95% CI 1.17, 2.45), being 
 married/living with a partner (OR 3.12, 95% CI 1.10, 8.87), or 
using instructions on pill bottle/package as an administration aid 
(OR 4.82, 95% CI 1.76, 13.22). In contrast, being aged ≥65 years 
was associated with poorer knowledge of medications (OR 0.24, 
95% CI 0.08, 0.71). Moreover, taking a greater number of preven-
tion medications was also associated with poorer knowledge of 
these medications, i.e., when compared to participants taking 
fewer (≤2) prevention medications, knowledge was worse among 
those taking three medications (OR 0.15, 95% CI 0.03, 0.66) or 
four or more medications (OR 0.09, 95% CI 0.02, 0.44).
DiSCUSSiOn
The educational intervention that we investigated was an integral 
part of a comprehensive, multifaceted intervention for second-
ary prevention of stroke. We adopted structured and tailored 
education of participants to improve knowledge of medications 
and skills for medication management. Despite this, we found 
no evidence for better knowledge of secondary prevention 
medications in the intervention group than control. Similarly, 
our intervention did not improve any of the measured attributes 
of medication knowledge relative to current practice.
Our finding is in contrast with that of a similar multifaceted 
study conducted in Israel (14). In that study, a tailored nursing 
intervention improved knowledge of important attributes of 
medication knowledge such as dosage, side effects, and what to 
do in response to side effects, at 3 months and 6 months post-
stroke. Moreover, knowledge of the timing of medications was 
significantly better in the intervention group than controls at 
TaBlE 4 | Per protocol analyses of the effect of intervention on knowledge of medications.
Medication knowledge Participants obtaining optimal scorea Univariable Multivariabled
intervention N (%) (n = 67) Control N (%) (n = 61) (Or, 95% Ci) (Or, 95% Ci) P-value
individual item score (optimal score = 1)b
Name of medication 43 (64.2) 38 (62.3) 1.08 (0.53, 2.23) 1.02 (0.43, 2.39) 0.967
Reasons for administration 38 (56.7) 35 (57.4) 0.97 (0.48, 1.96) 0.83 (0.35, 1.93) 0.659
Mechanism of administration 36 (53.7) 33 (54.1) 0.99 (0.49, 1.98) 1.00 (0.41, 2.45) 0.996
Timing of medication 60 (89.6) 57 (93.4) 0.60 (0.17, 2.17) 0.51 (0.14, 1.91) 0.321
Side effect 7 (10.5) 5 (8.2) 1.31 (0.39, 4.36) 1.47 (0.38, 5.77) 0.579
What to do when
Medication side effects occur 55 (82.1) 47 (77.1) 1.37 (0.58, 3.24) 1.47 (0.57, 3.79) 0.420
Dose of medication is missed 52 (77.6) 52 (85.3) 0.60 (0.24, 1.49) 0.74 (0.27, 2.06) 0.568
Composite scorec
Median (Q1, Q3) 5.5 (3.5, 6.0) 5.0 (3.7, 6.7) 1.02 (0.59, 1.78) 1.01 (0.38, 2.71)e 0.980
Optimal (≥5) 43 (64.2) 37 (60.7) 1.16 (0.57, 2.38) 0.87 (0.54, 1.40) 0.566
aAnalyses were restricted to 128 patients who were taking medications at 12 months.
bItem score was calculated as the sum of scores for an item divided by the number of medications assessed.
cComposite score was calculated as the sum of scores for all items divided by the number of categories of medications used.
dAdjusted for type of stroke, medical history, demographic, socioeconomic, mental and functional status, number of prescribed prevention medications, length of use of prevention 
medications, method by which medications are packaged/provided by pharmacist, and self-reported method(s) of keeping track of medications.
eExponentiated coefficient obtained from the stepwise multivariable linear regression analyses.
OR, odds ratio; CI, confidence interval.
TaBlE 3 | Univariable and multivariable analyses of the effect of intervention on knowledge of medications.
Medication knowledge Participants obtaining optimal scorea Univariable Multivariabled
intervention N (%) (n = 72) Control N (%) (n = 61) (Or, 95% Ci) (Or, 95% Ci) P-value
individual item score (optimal score = 1)b
Name of medication 48 (66.7) 38 (62.3) 1.21 (0.59, 2.47) 1.03 (0.46, 2.34) 0.938
Reasons for administration 42 (58.3) 35 (57.4) 1.04 (0.52, 2.07) 0.87 (0.39, 1.97) 0.751
Mechanism of administration 40 (55.6) 33 (54.1) 1.06 (0.53, 2.10) 1.17 (0.49, 2.78) 0.730
Timing of medication 64 (88.9) 57 (93.4) 0.56 (0.16, 1.96) 0.44 (0.10, 1.20) 0.219
Side effect 7 (9.7) 5 (8.2) 1.20 (0.36, 4.01) 1.27 (0.32, 4.98) 0.736
What to do when
Medication side effects occur 60 (83.3) 47 (77.1) 1.48 (0.63, 3.52) 1.58 (0.62, 4.00) 0.336
Dose of medication is missed 56 (77.8) 53 (85.3) 0.61 (0.24, 1.49) 0.71 (0.26, 1.95) 0.511
Composite scorec
Median (Q1, Q3) 5.6 (3.6, 6.0) 5.0 (3.7, 6.7) 0.92 (0.63, 1.85) 0.89 (0.56, 1.41)e 0.612
Optimal (≥5) 47 (65.3) 37 (60.7) 1.22 (0.60, 2.47) 1.10 (0.42, 2.92) 0.841
aAnalyses were restricted to 133 patients who were taking medications at 12 months.
bItem score was calculated as the sum of scores for an item divided by the number of medications assessed.
cComposite score was calculated as the sum of scores for all items divided by the number of categories of medications used.
dAdjusted for type of stroke, medical history, demographic, socioeconomic, mental and functional status, number of prescribed prevention medications, length of use of prevention 
medications, method by which medications are packaged/provided by pharmacist, and self-reported method(s) of keeping track of medications.
eExponentiated coefficient obtained from the stepwise multivariable linear regression analyses.
OR, odds ratio; CI, confidence interval.
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3  months after stroke. However, these findings may have been 
potentially biased by the non-randomized nature of the study 
design. Importantly, this difference in methodological approach 
hinders reliable comparison between the findings reported in the 
Israeli study and those observed in our study. Therefore, further 
research is needed in order to confirm the results of the present 
study, and to appropriately inform practice.
The lack of effect of the intervention undertaken in our 
study highlights the challenges in meeting medication infor-
mation needs of survivors of stroke, and emphasizes a clear 
need to optimize education strategies on use of secondary 
prevention medications. This could involve education tailored 
to individual learning abilities and skills. For instance, it is 
known that survivors of stroke are often less receptive to 
knowledge of secondary prevention measures than people with 
other conditions, as a result of their neurological deficits (19), 
or cognitive deficits related to old age (9). Therefore, specific 
education strategies or methods to overcome these learning 
abilities should be adopted.
Another possible explanation for the lack of effect of our 
intervention may be the long delay between education sessions 
(occurring at baseline and 3 months) and the outcome assessments 
(occurring at 12  months). The impact of the intervention may 
have diminished over this period, as any education or knowledge 
TaBlE 5 | Factors associated with knowledge of medications.
Characteristics Univariable Multivariablea
Or (95% Ci) P-value Or (95% Ci) P-value
Intervention 1.22 (0.60, 2.47) 0.582 1.10 (0.42, 2.92) 0.841
Aged ≥65 years 0.27 (0.12, 0.61) 0.002 0.24 (0.08, 0.71) 0.010
Male 0.83 (0.39, 1.77) 0.621 2.69 (0.83, 8.76) 0.100
Vocational or higher degree 1.88 (0.91, 3.84) 0.085 – –
High socioeconomic positionb 2.64 (1.27, 5.47) 0.009 4.79 (1.76, 13.07) 0.002
Married or living with partner 3.76 (1.72, 8.21) 0.001 3.12 (1.10, 8.87) 0.033
Recurrent stroke 0.62 (0.22, 1.72) 0.353 – –
≥2 comorbidities 0.68 (0.34, 1.39) 0.290 – –
Prescribed secondary prevention medications
≤2 1.0 1.0 –
3 0.21 (0.06, 0.70) 0.011 0.15 (0.03, 0.66) 0.013
≥4 0.17 (0.05, 0.55) 0.003 0.09 (0.02, 0.44) 0.003
Provided medications in pill bottle/package 11.87 (2.51, 56.20) 0.002 – –
Keep track of medications using instructions on pill bottle/package 4.20 (1.96, 8.98) <0.001 4.82 (1.76, 13.22) 0.002
Using prevention medications for ≥2 years 0.99 (0.49, 2.01) 0.972 – –
Increased ability (per 0.1 LHS) 1.68 (1.29, 2.21) <0.001 1.69 (1.17, 2.45) 0.006
Depressed (HADS >7) 0.47 (0.17, 1.31) 0.147 – –
Anxious (HADS >7) 1.52 (0.58, 3.98) 0.391 – –
aMultivariable model was adjusted for all other factors in the column.
bSocioeconomic position determined using Australian Socioeconomic Indexes for Areas based on postcode.
LHS, London Handicap Scale; HADS, Hospital Anxiety and Depression Scale; OR, odds ratio; CI, confidence interval.
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acquired may be forgotten over time. Strategies to reduce this 
loss of knowledge could involve the use of reminders or more 
frequent delivery of education or follow-up, to reinforce informa-
tion on use of medications, so that knowledge is maintained in 
the long term. Pharmacists can play a crucial role as reminders of 
important prescription information when providing refills after 
hospital discharge, although the impact of such intervention on 
patient medication knowledge is unknown.
In the present study, although ≥80% of participants knew what 
to do when experiencing medication side effects, they rarely knew 
what side effects could occur (<10%). Similarly, in Israel, more 
than 70% of participants knew what to do when experiencing 
side effects, but knowledge of side effects was only moderate (14). 
Knowledge of side effects is very important in secondary preven-
tion, facilitating prompt response to medication-related adverse 
reactions (20), or reducing fear of severe medication-related 
complications (21).
Our observation that 35% of our participants had incorrect 
or no knowledge of fundamental attributes of their medications, 
such as the names of the medications, was better than that 
reported in an Israeli study (14). However, better knowledge 
of reasons for administration of medications was reported in 
other patient groups (≥82%) (22), than those found in our study 
(58%). It is important to acknowledge that our estimates may 
not be easily compared with those reported in previous studies 
because of differences in the methods used to assess medication 
knowledge. However, these findings still highlight the gaps in 
meeting information needs regarding medication regimens in 
patients with stroke.
Similar to our findings, others have reported that older age 
having a low income, being disabled, and increasing polyphar-
macy, are associated with poor knowledge of medications in 
other patient groups (4, 17). These patients are at greater risk 
of poor knowledge and are more likely to benefit from targeted 
and intensive intervention to improve knowledge of medica-
tions. Therefore, these factors should be taken into consideration 
when designing education strategies for secondary prevention 
of stroke.
An important and novel finding of this study is the impor-
tance of instructions on the prescription container as a major 
source of information on medications. Indeed, in the present 
study, participants that reported using instructions on pill bot-
tles/package to keep track of their medications had significantly 
better knowledge of their medications than those using other 
dose administration aids, such as dosette boxes and bubble 
packs. To further explain this finding, we investigated the possi-
bility of type of dose administration aid being a surrogate for the 
number of comorbidities presented by an individual. However, 
when number of comorbidities was forced into the regression 
model, there was no substantial change in the original estimates 
(odds ratios) observed for the variables retained in the model. 
Therefore, the role of methods by which medications are pro-
vided for improving general long-term medication management 
remains unclear.
An important limitation of our study is the lack of baseline 
data on knowledge of medications to determine a change over 
time between groups. This limitation arose because this sub-study 
was conceived after the commencement of the main trial to fill 
an important evidence gap on the improvement of medication 
knowledge in secondary prevention of stroke. However, the level 
of balance observed between study groups at baseline is reflective 
of the successful randomization procedure used in this study. 
Therefore, it is unlikely there was any significant difference in 
knowledge between study groups at baseline. Our study is also 
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limited by a small sample size that could affect the robustness 
of the estimates on the efficacy of our intervention, and limit 
the power to identify factors associated with better knowledge 
of medications. Our findings may not be representative of the 
wider stroke population as a result of potential selection bias. 
For instance, the present study was conducted in community-
dwelling survivors of stroke or TIA, thereby excluding people 
with severe stroke. Moreover, only 22% of the patients who met 
eligibility criteria were enrolled to the main trial. However, it 
is important to acknowledge that poor rate of recruitment is a 
common phenomenon in stroke trials (23). A major strength of 
our study is the robust study design. When compared to similar 
studies (14, 22), the randomized controlled design used in the 
present study limited potential bias from confounding factors. 
Therefore, our findings provide a more reliable basis for further 
research.
In conclusion, our study did not provide evidence for the 
effectiveness of a nurse-led, community-based educational 
intervention for improving knowledge of secondary preven-
tion medications in survivors of stroke or TIA. As limited data 
exist on this topic, our findings provide a rationale for further 
investigating strategies to improve knowledge of medication in 
this high-risk population. Importantly, we have identified sub-
groups of patients who are at greater risk of poor knowledge 
of their secondary prevention medications, and are therefore 
groups most likely to benefit from more intensive educational 
intervention.
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